ArticlePolymers2021
QbD Enabled Azacitidine Loaded Liposomal Nanoformulation and Its In Vitro Evaluation.
Article in Polymers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 60 citations in OpenAlex.
- Investigating the Potential of High Permeation Vesicle-Based Methotrexate Gel for Localized Therapy in Rheumatoid Arthritis.Pharmaceutical research · 2026Article
- Synergistic combinatorial anticancer potential of Tamoxifen with Naringin and Diosmetin in MCF-7 breast cancer cells and their liposomal delivery.Scientific reports · 2026Article
- Design of Experiments (DoE) Driven Fabrication of Surface Modified Liposomes of Olmesartan Medoxomil for Improved Oral Bioavailability.AAPS PharmSciTech · 2025Article
- Apolipoprotein-decorated drug loaded liposomes mitigating copper intoxication: an in vitro and in vivo evidence-based study intervening Wilson disease.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators.The Yale journal of biology and medicine · 2025Review
- Enhanced therapeutic effects of all-trans retinoic acid nanostructured lipid carrier composite gel drug delivery system for alopecia areata.Journal of nanobiotechnology · 2025Article
- Ceftriaxone-Loaded Liposomal Nanoparticles for Pulmonary Delivery Against Lower Respiratory Tract Infections: Development and Characterization.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting the epigenome with advanced delivery strategies for epigenetic modulators.Bioengineering & translational medicine · 2025Review
- Mapping the Landscape of Anti-Breast Cancer Drug Discovery in Saudi Arabia: A Bibliometric Analysis (2019-2023).Scientifica · 2025Article
- Preparation and Characterization of Universal Liquid Proliposomes Encapsulating Water-soluble Efficacious Substances.Current pharmaceutical biotechnology · 2025Article
- Efficient Delivery of Gold Nanoparticles and miRNA-33a Via Cationic PEGylated Niosomal Formulation to MCF-7 Breast Cancer Cells.AAPS PharmSciTech · 2024Article
- BrSPR-20-P1 peptide isolated fromRSC advances · 2024Article
- Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.Drug delivery and translational research · 2024Article
- pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor.Drug delivery and translational research · 2023Article
- Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.Materials (Basel, Switzerland) · 2023Article
- The effect of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) Addition on the physical characteristics of β-ionone liposomes.Scientific reports · 2023Article
- Pentapeptide cRGDfK-Surface Engineered Nanostructured Lipid Carriers as an Efficient Tool for Targeted Delivery of Tyrosine Kinase Inhibitor for Battling Hepatocellular Carcinoma.International journal of nanomedicine · 2023Article
- Quality by Design Approach in Liposomal Formulations: Robust Product Development.Molecules (Basel, Switzerland) · 2022Review
- Optical Imaging of Epigenetic Modifications in Cancer: A Systematic Review.Phenomics (Cham, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Azacitidine (AZA), an inhibitor of DNA methyltransferase, is a commonly recognized drug used in clinical treatment for myelodysplastic syndrome and breast cancer. Due to higher aqueous solubility and negative log P of AZA causes poor cancer cell permeation and controlled release. The objective of the present study was to formulate and optimize AZA-loaded liposome (AZA-LIPO) for breast cancer chemotherapy by using Box Behnken design (BBD) and in vitro evaluation using MCF-7 cells. AZA-LIPO were prepared using a thin film hydration technique and characterization study was performed by using FTIR and DSC. The prepared formulations were optimized using BBD and the optimized formulation was further subjected for particle size, surface charges, polydispersity index (PDI), drug loading, entrapment efficiency, TEM, XRD, in-vitro drug release and hemolytic toxicity. The mean particle size of optimized AZA-LIPO was 127 nm. Entrapment efficiency and drug loading of AZA-LIPO was found to be 85.2% ± 0.5 and 6.82 ± 1.6%, respectively. Further, in vitro drug release study showed preliminary burst release in 2 h followed by a sustained release for 36 h in phosphate buffer at different pH (4.0, 5.5, and 7.4) as compared to free drug. Drug release was found to be pH dependent, as the pH was increased, the drug release rate was found to be low. Time-dependent cell viability assay exhibited significant higher cell viability and higher internalization than free AZA in MCF-7 cells. AZA-LIPO were more effective than the free AZA in reducing Bcl2 expression, while increasing pro-apoptotic Bax and caspase-3 activity. The result showed that the formulated biocompatible AZA-LIPO nano-formulations may be used as an efficient anti-cancer drug delivery system for the treatment of breast cancer after establishing preclinical and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.